Hope S. Rugo, MD

Hope S. Rugo, MD, a medical oncologist and Director of the Breast Oncology Clinical Trials Program at University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses 5-year follow-up data from the CALGB 40502//NCCTG N063H study, which was a randomized phase III trial of weekly paclitaxel (Abraxane) compared with nab-paclitaxel or ixabepilone (Ixempra) with bevacizumab (Avastin) as first-line chemotherapy for locally recurrent or metastatic breast cancer.

Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the 5-year follow-up of the CALGB 40502 study for patients with triple-negative breast cancer (TNBC).

Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant endocrine therapy for patients with HR+ breast cancer.

Hope S. Rugo, MD, discusses the differentiating factors of abemaciclib among the CDK 4/6 inhibitors for breast cancer treatment.

Hope S. Rugo, MD, discusses the final overall analysis of the phase II MONARCH 1 trial, which explored the use of abemaciclib for the treatment of patients with pretreated hormone-receptor (HR)-positive/HER 2-negative advanced breast cancer.

Hope Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses targeting the androgen receptor in breast cancer.

Hope S. Rugo, MD, professor of Medicine and director of the Breast Oncology Clinical Trials Program at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses what sets abemaciclib apart from other CDK 4/6 inhibitors in the field of hormone receptor (HR)-positive breast cancer.

Hope Rugo, MD, clinical professor, department of medicine, and director of Breast Oncology Clinical Trials Program, at University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses the role of immunotherapy in breast cancer.

Hope S. Rugo, MD, clinical professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology Clinical Trials Program, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, discusses patient selection for premenopausal endocrine therapy.

Hope S. Rugo, MD, from the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses new guidelines for the treatment of patients with metastatic breast cancer.

Hope S. Rugo, MD, from the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses pathway changes in breast cancer.